

Cover Story
Free
By Matthew Bin Han Ong
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
By Laura Brawley
In Brief


Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology













